4.52 USD
▲-0.21+2.96%
盘后 4.45 +1.37%
2026-08-03
市值
$448.28M
市盈率
—
EPS
-0.99
股息率
—
52 周区间
0.75 – 5.69
成交量
218.80K
Beta
0.95
目标价
8.00
52W 低 0.7552W 高 5.69
价格走势
公司简介
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCel...